Addictions are chronic brain diseases that can be treated medically
Opiant is a speciality pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose.
The numbers
More than 20 million people in the United States live with a substance-abuse disorder, but only 10% of those affected receive treatment for their condition
with emergency room visits with Acute Cannabinoid Overdose
with Alcohol Use Disorder
with Opioid Use Disorder and 70k opioid-related overdose deaths annually in the USA
OPIANT AND SUBSTANCE USE DISORDERS
Our Pipeline
To address the diverse and mounting demands of modern-day substance use, Opiant is advancing a pipeline of scientifically-informed treatment approaches.
Spotlight
The latest from Opiant
Overdose deaths top 100,000 in a single year
November 18, 2021 – As overdose deaths top 100,000 in a single year, Opiant CEO Dr. Roger Crystal on how fentanyl has worsened the opioid crisis, the importance of overdose preparedness, and Opiant’s work to confront this public health issue.
NBC4 News: Overdose on LA street
October 8, 2021 – Opiant CEO, Dr. Roger Crystal, used NARCAN® Nasal Spray to treat a man suffering an apparent opioid overdose on an LA street.
News Tonight with Chance Seales
October 7, 2021 – In an interview with Chance Seales on News Tonight, Dr. Roger Crystal, Opiant CEO, spoke about the approaches we can take to treat opioid use disorder and opioid overdose in the U.S.
Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
SANTA MONICA, Calif. , Nov. 11, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions…
Opiant Pharmaceuticals to present at Jefferies Virtual London Healthcare Conference
SANTA MONICA, Calif. , Nov. 10, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (Nasdaq: OPNT), a company advancing medicines to better treat addictions and…
Opiant Receives FDA Fast Track Designation for OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
Fast Track Designation further underscores the potential for OPNT003 to represent a major advance in the treatment of opioid overdose as opioid overdose deaths surge…
November 18, 2021 3:00 PM EST : Jefferies Virtual Healthcare London Conference
November 11, 2021 4:30 PM EST : Opiant Pharmaceuticals Third Quarter 2021 Financial Results Conference Call
August 5, 2021 4:30 PM EDT : Opiant Pharmaceuticals Second Quarter 2021 Financial Results Conference Call
Cannabinoid1 (CB‐1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose
Published in 2020 by the Journal of Neural Transmission.
Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose
Published in April 2019 by ASPET Journals.
Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects
Published in March 2019 by American College of Neuropsychopharmacology.
Lessons from a doctor and CEO on the US’s opioid crisis
April 14, 2020 – Roger Crystal set out to impact healthcare at a ‘societal’ level. The doctor who developed the NARCAN® Nasal Spray says he is proud to see its impact on the opioid crisis in the United States: the opioid overdose reversal medicine has saved a large number of lives.
Opiant donates to organizations supporting patients vulnerable to substance use disorders during COVID-19
Opiant donated $40,000 to the International Association of Fire Fighters Foundation, the Association of Recovery in Higher Education, the Harm Reduction Coalition and the UK’s Action on Addiction.
A Prescription for Tackling the Opioid Overdose Crisis – A Panel Discussion
Although the opioid crisis has resulted in close to 600,000 deaths since 1999, evidence shows that increasing the availability of naloxone—a prescription medication that reverses the respiratory depression caused by an opioid overdose—reduces the rate of opioid overdose deaths.